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Acute myeloid leukemia (AML) is a genetically heterogeneous disease characterized by 
uncontrolled proliferation of precursor myeloid-lineage cells in the bone marrow. AML 
is also characterized with patients with poor long-term survival outcomes due to relapse. 
Many efforts have been made to understand the biological heterogeneity of AML and the 
challenges to develop new therapies are therefore enormous. G protein-coupled receptors 
(GPCRs) are a large attractive drug targeted family of transmembrane proteins, and 
aberrant GPCR expression and GPCR-mediated signaling have been implicated in 
leukemogenesis of AML. This review aims to identify the molecular players of GPCR 
signaling, focusing on the hematopoietic system, which are involved in AML to help 
developing novel drug targets and therapeutic strategies. 
 
Methods: We undertook an exhaustive and structured search of bibliographic databases 
for research focusing in GPCR, GPCR signaling and expression in AML. 
 
Results and Conclusion: Many scientific reports were found with compelling evidence 
for involvement of aberrant GPCR expression and perturbed GPCR-mediated signaling 
in the development of AML. The comprehensive analysis of GPCR in AML provides 
potential clinical biomarkers for prognostication, disease monitoring and therapeutic 
guidance. It will also help to provide marker panels for monitoring in AML. We conclude 
that GPCR-mediated signaling is contributing to leukemogenesis of AML, and postulate 
that mass spectrometry-based protein profiling of primary AML cells will accelerate the 
discovery of potential GPCR related biomarkers for AML.  




Among the four main types of leukemia, acute myeloid leukemia (AML) is the deadliest 
with a 5-year survival rate of only 27% [1]. Leukemia is the broad term of hematopoietic 
cancers, thus affecting the immune cells in or from the bone marrow. Leukemia can 
develop slowly or very fast (i.e. chronic or acute), and can affect both the myeloid and 
lymphatic linage of the hematopoietic system. AML is characterized by uncontrolled 
proliferation of limited differentiated myeloid cells in the bone marrow [2-4]. 
Accumulation of these cells often results in reduced number of healthy and mature 
hematopoietic cells such as leukocytes, red blood cells and platelets in the blood and 
lymphoid organs. Patient heterogeneity is considerable in terms of the cellular phenotype 
(i.e. morphology, cytogenetic aberrations and mutations) and clinical outcome [3]. The 
prognosis is decided by cytogenetic and molecular abnormalities, and these factors are 
used to stratify AML patients into the following risk groups: favorable, intermediate and 
poor [4].  
Advancing age, male gender and region of diagnosis are other risk factors [5], with age 
being the most pronounced. The prognostics will further guide the therapeutic decisions, 
such as who would benefit from an allogeneic hematopoietic stem cell transplantation 
(allo-HSCT) in their first complete remission, as even patients with a favorable risk have 
35-40% chance of leukemic relapse (without allogeneic stem cell transplantation) [6].  
To complicate the matter further, the leukemic cell population derived from a single 
patient can include different subpopulations of cells (i.e. cells with different genetic 
abnormalities and/or at different stages of maturation). Of particular importance is 
perhaps the leukemic stem cell (LSC) in the hierarchically organized cell population. This 
rare cell population (1 in 1.6 x103 to 1 in 1.1 x 106 cells) can be defined by functional 
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assays, and their immunophenotype (i.e. surface molecule profile) differs between 
patients [7]. 
Important efforts have been put into understanding the biological heterogeneity of AML, 
aiming at improving the prognostication and therapy. This review will focus on 
involvement of G protein-coupled receptor (GPCR)-mediated signaling in cancer, 
especially in leukemogenesis of AML.  
GPCRs are a large family of seven transmembrane receptors that binds a variety of 
endogenous ligands, including inflammatory mediators like chemokines and cytokines 
(reviewed in [8] and [9]). Proper GPCR signaling is essential in response to inflammation 
as well as critical for cell proliferation, survival and differentiation. Thus, receptor 
blocking with novel GPCR antagonists or inhibitors against their membrane-associated 
heterotrimeric G proteins or protein regulators are attractive cancer drug targets. The field 
of GPCR signaling is enormous and very well reviewed (as it will be acknowledged along 
this review). In this review we will just give a brief introduction of the main players in 
GPCR signaling to, then, focus in the recent achievements on GPCR signaling in AML. 
This information provides tools for researchers to explore future therapeutic targets. 
 
GPCR signaling 
Many hormones, neurotransmitters, chemokines, odorants, ions and other stimuli act 
through the activation of different GPCRs that transmit the signal across the plasma 
membrane activating a number of signaling pathways [10]. Of those, the heterotrimeric 
G proteins, considered the canonical effectors, and arrestins are best characterized [11]. 
In the presence of ligand, GPCR undergoes an important rearrangement of internal helices 
6 and 3 [12] that in turn triggers the exchange of GDP for GTP (acting as guanine 
nucleotide exchanges factors) on Gα, and their dissociation from G that results in the 
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activation of a plethora of downstream effectors. The cycle is terminated with the 
hydrolysis of GTP to GDP on Gα, a process accelerated by specialized proteins named 
Regulators of G protein Signaling (RGS) (acting as GTPase-activating proteins, i.e. 
GAPs)[13-14] and the re-formation of the heterotrimer. Further termination of the signal 
involves the phosphorylation of GPCR by specialized G protein receptor kinases (GRKs) 
and the binding of arrestin proteins [15] with the concomitant internalization of GPCRs. 
Internalization is also important for signaling since it has recently been proven that 
GPCRs can continue signaling once internalized in vesicles [16]. On the other hand, 
arrestin proteins can, in turn, act as adaptor proteins initiating alternative signaling 
cascades [17] (see figure 1). Furthermore, some ligands selectively activate certain 
pathways at the expense of others. This process has prompted the search of specialized 
ligands, named biased agonists, for selective drug development that can distinguish the 
activation through G proteins from the arrestin-based signal [18].  
 
GPCRs 
The GPCRs superfamily shares a common structure with seven transmembrane helices 
and can be grouped into several subfamilies [19-20]. Class A (rhodopsin-like), by far the 
largest and most studied in humans (more than 700 receptors), binding of the allosteric 
ligand produces the well-documented shift of the α-helices; Class B1 (secretin receptor-
like) and Class B2 (adhesion receptors), with a large extracellular N-terminal domain 
which contains the high-affinity binding site for their peptide ligands; Class C 
(metabotropic glutamate receptor-like), work as homo- or hetero-dimers and also have a 
large N-terminal domain with a bilobal Venus flytrap domain (VFT); and class F 
(frizzled-like) subfamilies as well as the taste 2 sensory receptor subfamily. High 
conformational flexibility is a hallmark of GPCRs that together with other modifications 
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allow them to sense diverse stimuli. Those can regulate the receptor activity through 
conformational selection of distinct states that in turn selects the signaling response [21]. 
Among the downstream GPCR-interacting molecules are multiple adaptor and 
modulatory proteins, besides G proteins and arrestins, such as PDZ-containing scaffolds 
and non-PDZ-scaffolds. The latest revolution in cryo-electron microscopy and structural 
biology has allowed the comprehension of the conformational dynamics upon ligand 
binding and its control in the signaling output [18, 22-23].  
 
G-proteins  
Although the amount of GPCR family members comprises over 800 members in the 
human genome, there are a relatively small number of G proteins that trigger a high 
number of intracellular signaling cascades [24]. A comprehensive analysis of the 
determinants of GPCR-G protein binding for the entire GPCR-G-protein signaling system 
has been recently released [25]. Thirty-five different genes encoding for G proteins can 
be found in the human genome, of which 16 correspond to G-subunits, 14 to G and 5 
to G [26]. The four major G families Gs, Gi, Gq, and G12 [27] regulate different key 
effectors (for example, adenyl cyclase by the Gi/Gs, phospholipase C (PLC) by the Gq 
subfamily, Rho by G12 subfamilies) that generate secondary messengers, which trigger 
different signaling cascades. The Gi subfamily is blocked by pertussis toxin and thereby 
many different signaling pathways are inhibited, among them chemotaxis triggered by 
chemokines. The Gq family embraces four members: Gq and G11 (ubiquitously 
expressed and with close protein sequence similarity), G14 (found in kidney, liver and 
lung) and G15/16 (mouse/human orthologous respectively, expressed only in 
hematopoietic and epithelial cells) [28]. To date functional redundancy has been assumed 
for Gq and G11, with few exceptions [29-30]. Besides, both are present in most cells 
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except for platelets [31] and purkinje cells [32]. Phospholipase C  is considered to be 
the canonical effector of the Gq family, although an extensive variety of cellular proteins 
have been described to interact with Gq that can either function as effectors, regulators 
or be considered as accessory proteins [24]. Different non-canonical functions and 
locations of Gq proteins have also been shown, as the control of mitochondria physiology 
[33]. The role of Gq/G11 in regulating multiple cellular and physiological functions is 
well established: controlling cardiovascular physiology; smooth muscle tone and nervous 
system [34].  
On the other hand, another member of the Gq family, G15, is quite unique in sequence 
and properties [35]. G15/16 can couple with a variety of GPCRs for PLC activation and 
subsequent Ca2+ mobilization and downstream signaling in the cells [28] [36] [37]. 
Moreover, G15-coupled signaling is quite resistant to GPCR-internalization by arrestins 
[35, 38] and is phosphorylated by protein kinase C (PKC) [39]. Although all these 
properties confer the protein’s functional differences, its specific function has remained 
quite elusive. But on the other hand, these properties have been used to make Gα15 as a 
laboratory tool for functional studies of ligand binding to orphan GPCRs [37, 40-41], 
reviewed in [38].  
 
Regulators of GPCR signaling: RGSs, GRKs, and Arrestins  
RGS Proteins 
The prototype role of RGS proteins is the acceleration of GTP hydrolysis by G 
promoting the re-association of G and Gβγ subunits with the receptor. RGS stabilize the 
transition state conformation lowering the free energy required for the hydrolysis reaction 
[42-43]. Hence, they regulate the magnitude and duration of the cellular response by 
GPCRs [42, 44]. There are 20 canonical members of the RGS family in mammals grouped 
8 
 
in four subfamilies. Almost all containing a core domain of 120 amino acid, i.e. the RGS-
domain, which mediates interaction to G subunits. Additionally, they contain non-RGS 
domains or modulatory regions that either gives G-protein specificity or additional roles 
[45]. Multiple RGS proteins are expressed in a given cell and tissue making the study of 
their physiological function very challenging. Nevertheless, along the years many studies 
have contributed to understand their involvement in the control of many physiological 
processes including cardiovascular biology, metabolism, inflammation and 
neurophysiology [46-47]. On the other hand, RGS are implicated in multiple pathologies 
such as cardiovascular (hypertension and atherosclerosis) and neurodegenerative 
disorders (schizophrenia, depression, addiction, anxiety and many others) [13, 48], and 
references herein. RGS proteins are key modulators of many physiological systems and 
they are tightly regulated by different mechanisms ranging from protein subcellular 
localization, protein stability, transcriptional control or epigenetic regulation.  
 
GRKs  
G protein receptor kinases (known as GRK) are members (7 in mammals) of the AGG 
kinase family that specifically recognize and phosphorylate agonist-bound GPCRs in the 
C-terminal tail and/or cytoplasmic loop [49-51] and, together with arrestins, are part of 
the mechanism for desensitization of the response. The GRK family members are 
multidomain proteins with a central catalytic domain necessary for the phosphorylation 
of serine/threonine residues at the C-terminal and internal loops of the agonist-stimulated 
GPCRs. GRKs can be subdivided into three main groups: visual GRK (GRK1 and 
GRK7), the β-adrenergic receptor kinase (GRK2 and GRK3) and the GRK4 subfamily 
(GRK4, GRK5 and GRK6). The non-catalytic domain of the GRKs houses the regions 
(like RH and PH domains) involved in the interaction to other cellular partners and 
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regions for modulation of their activity that coordinate the recruitment and activation of 
the different isoforms [51]. GRK2 is the most abundant and studied isoform and is the 
isoform that provided the finding that GRK-mediated phosphorylation promoted GPCR 
endocytosis [52]. Further it was proven that GRK2 interacts with several proteins that are 
involved in or regulates the endocytosis process, like clathrin, GRK-interacting protein 1 
(GIT1), phosphoinositide-3-kinase (PI3K) and ezrin. More recently, it has been shown 
that GRK2 displays a complex interactome, for instance it interacts with Gq, mitogen-
activated protein kinase kinase (MEK), serine-threonine protein kinase (AKT) and Raf 
kinase inhibitor protein (RKIP) [53-54]. This led to the suggestion that GRKs, as 
arrestins, can act as scaffold proteins to form signaling platforms on the receptor [17, 55-
56]. GRK2 participates in basic cellular processes such as migration, cell-cycle 
progression, among others.  
 
Arrestins 
Arrestins are small globular proteins that bind specifically to the broad family of active 
phosphorylated GPCRs and numerous non-receptor partners [57]. The arrestin family has 
four members in mammals:  arrestin-1 (known as visual or rod arrestin); arrestin-2 (also 
called -arrestin-1); arrestin-3 (-arrestin-2) and arrestin-4 (cone arrestin). Arrestins 
modulate GPCR activation by direct competition with G proteins [58]. Their recruitment 
to phosphorylated GPCRs arrest G protein binding through steric hindrance and induces 
receptor internalization from the cell surface through clathrin-coated vesicles [59-61]. It 
is well documented that arrestins can also serve as adaptor/scaffold proteins that connect 
and promote multiple independent signaling pathways [17, 62-63]. Their high flexibility 
ensures their ability to scaffold multiple proteins [64]. Arrestins, β-arr1 and β-arr2, 
present different properties in terms of their affinity for GPCRs, subcellular localization, 
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interacting partners and signaling [17, 52, 65-66]. Extracellular signal-regulated kinase 
1/2 (ERK1/2) is one of the best characterized example of interaction partners, but proto-
oncogene tyrosine kinase Src [67], small GTPases, transcription factors, PI3K/AKT 
proteins, proteins from the wingless-type MMTV integration site family (Wnt)/β-catenin 
pathway [68-69] and cytoskeletal proteins are also included (see [57] for extended list). 
Surprisingly, two recent studies [70-71] have suggested that arrestins control the 
amplitude and kinetics of ERK, as other multiple studies have shown, but only in the 
presence of G proteins. What it is clear is that arrestins acting as scaffolds, bind key 
pathway intermediates that influence the tonic level of pathway activity in cells and, in 
some cases, serve as ligand-regulated scaffolds for GPCR-mediated signaling [72-73]. 
Therefore, arrestins play important roles in embryological development, perhaps 
reflecting their interaction with non-GPCR elements of the Sonic hedgehog (Shh)-
Smoothened, Wnt, and Notch signaling pathways [68].  
 
GPCR signaling in hematopoietic cells 
GPCRs in hematopoietic cells 
G protein–coupled receptors (GPCRs) are expressed in hematopoietic cells and their 
function is only partially understood (see model in Figure 1). Hematopoietic cells change 
location during development and circulate in mammals throughout life, moving in and 
out of the bloodstream to engage different niches. The interaction with the surrounding 
environment is very important for the regulation of the hematopoietic cell fate. The 
migration and circulation of various types of blood cells is regulated by chemokines in 
particular, membrane proteins, its GPCRs, and other GPCRs expressed in hematopoietic 
and lymphoid tissues [74]. CXCL12 (also called SDF-1) is one of the most abundant and 
important chemokine that regulates HSC (hematopoietic stem cells) quiescence and 
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differentiation [75-76]. CXCR4, the receptor for CXCL12, is expressed by more than 
95% of  hematopoietic cells in bone marrow including HSCs and hematopoietic 
progenitors. CXCL12 is expressed by heterogeneous populations of cells: mesenchymal 
stem and progenitor cells (MSPCs) and sinusoidal endothelial cells, which express the 
highest amounts, as well as osteoblasts besides certain hematopoietic cells. In addition, 
other cytokines such as granulocyte colony-stimulating factor (G-CSF) act partially 
through the modulation of CXCL12/CXCR4 signaling to induce hematopoietic stem cell 
mobilization in the bone marrow [77-78]. CXCL12 can also cross-talk with other GPCR 
signaling pathways, including sphingosine-1-phosphate (S1P) and Lipoprotein (A) (LPA) 
[79]. Both S1P and LPA synergistically enhance the chemotactic migratory response of 
the hematopoietic stem cells to CXCL12 [80-82]. 
The complement receptor C3aR is another inflammatory GPCR [83]. Similar to CXCR4 
antagonists, blocking of C3aR augmented G-CSF mobilization of hematopoietic cells 
[84]. Interestingly, expression of endocannabinoids by stromal cells modulate G-CSF 
mobilization via  the endocannabinoid receptor CB2 [85], but in contrast to antagonists 
of CXCR4 and C3aR, which promote circulation of hematopoietic cells, CB2 antagonists 
reduced G-CSF–induced stem cell mobilization [86]. Other GPCRs expressed in 
hematopoietic stem cells are the cysteinyl leukotriene D4 receptor (cysLT1) [87] and 
lysophospholipid receptors such as S1PR1 that differentially regulate chemotaxis, 
adhesion, and proliferation [88]. The co-activation of both Gq and Gi by cysLT1 results 
in stronger proliferation of hematopoietic stem cells than stimulation of Gi by CXCL12 
or S1P alone [88]. 
On the other hand, about one-third of the 33 human adhesion GPCRs are expressed in 
hematopoietic stem, progenitor, or mature cells, where they define distinct cellular 
populations (see [89]for an extensive study of adhesion GPCRs in immune system). In 
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particular, G protein-coupled receptor 56 (GPR56) is a versatile marker for all human 
cytotoxic lymphocytes, including natural killer (NK) cells and CD4+ and CD8+ T cells 
[90]. Interestingly, in a whole-blood gene expression meta-analysis in 14,983 individuals 
of European ancestry, GPR56 was the second most highly upregulated gene associated 
with age [91]. CD97 is expressed in both immature hematopoietic stem and progenitor 
cells (HSPCs), as well as more differentiated peripheral blood cells. Adhesion G Protein-
coupled receptor L1 (LPHN1), GPR124, GPR125, Cadherin EGF LAG seven-pass G-
type receptor 3 (CELSR3), GPR113, GPR114, and GPR126 are equally expressed in 
hematopoietic progenitor cells and granulocytes. GPR125 is expressed in noncommitted 
HSPCs (CD34+ CD45RA−) and also in B cells and erythroid precursors. In contrast, 
expression of CD97, Egf-Like Module-Containing Mucin-Like Hormone Receptor-Like 
2 (EMR2), and EMR3 is low in HSPCs, but gradually increases upon differentiation, 
reaching maximum expression levels in terminally differentiated mature peripheral blood 
granulocytes.  
 
Gq subfamily in hematopoietic cells 
Although the different members of the Gq subfamily of G proteins are present in the 
hematopoietic cells where they couple to different membrane receptors, their role in 
hematopoiesis has remind controversial. On one hand, Gq/11 has been shown to couple 
to some chemokine receptors (CCR2, CXCL12 and CXCR4) [92-95], but it doesn’t seem 
to be required for leukocyte chemotaxis that it is mainly driven by Gi proteins [96]. Other 
GPCR receptors present in hematopoietic cells also couple to both Gi and Gq/11. On the 
other hand, it was shown that Gq-deficient (GNAQ−/−) monocytes are unable to migrate 
to inflammatory sites and lymph nodes in vivo, demonstrating that Gq-coupled 
chemokine receptor signaling pathway may be needed for the initiation of the immune 
13 
 
responses [93]. Notably, Gi and Gq/11 proteins are involved in dissemination of myeloid 
leukemia cells to liver and spleen, whereas bone marrow colonization involves only 
Gq/11 [97]. Therefore, Gq activation could contribute to determining the commitment 
and threshold of hematopoietic cells either to migration or activation [98] (see [8] for a 
recent review). 
 As mentioned before one feature of G15 is its high degree of promiscuity, 
 its presence in immature bone marrow cells and, that its expression decrease upon cell 
maturation [99]. In particular it has been shown that G15 expression is mainly present 
with the CD34 marker for stem and progenitor cell population [100-101]. Consistent with 
this several chemokine receptors like CCR1, CCR2, CXCR1 and CXCR2 have been 
shown to couple to G15. These receptors utilize G15 to activate nuclear factor NF-
kappa-B (NF-κB) [38, 102-103]. Likewise, chemoattractant receptors such as CCR8, C3a 
and C5a have been reported to activate NF-κB via G15 [102, 104]. Moreover, CCR1-
induced STAT3 (signal transducer and activator of transcription 3) tyrosine 
phosphorylation and subsequent production and release of the chemokine CXCL8 in 
THP-1 macrophage like cells can also be mediated through G15 signaling [105]. 
Therefore, it was quite puzzling the results that show Gα15 knockout mice display normal 
maturation of all cell lineages and a normal response to the immune challenges [106]. 
Another feature of G15 is its resistance to arrestin-dependent desensitization. Taking this 
into account, it has been proposed that G15 could be relevant in exceptional conditions, 
as could be the case of intense GPCR activation in high proliferation states, in certain 
immune responses or in cases like cancer [35].  
 
RGS in hematopoietic cells 
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Importantly, RGS proteins are highly enriched in the hematopoietic compartment and 
their function have been associated with the immune system and with hematopoiesis and 
platelet formation [107]. For example, RGS1, RGS2, RGS10, RGS13 and RGS18 are 
expressed in lymphocytes (see [108] and [109] for details). Perhaps the most important 
G-protein-coupled receptors in lymphocytes regulated by RGS proteins are the 
chemokine receptors. Of interest is the fact that RGS1, RGS3, RGS4, and RGS13 in B 
lymphocytes and RGS16 in T cells impair chemokine-induced signaling [110-114]. In 
particular, RGS1-deficient mice are hyper-responsive to the chemokines CXCL12 and 
CXCL13, which results in abnormal architecture of the spleen [115]. RGS2 targeted 
mutation in mice cause a reduction in T-cell proliferation [116]. On the other hand, 
hypertension in humans is associated with reduced expression of RGS2 or mutations in 
its gene [117-119]. RGS13 is expressed in B and T lymphocytes and mast cells and its 
function has been associated to B and T-cell migration and/or differentiation besides 
controlling mast cell allergic inflammation [120].  RGS13 function is also associated to 
CXCR4-mediated migration of T cells [121]. On the other hand, other reports have 
demonstrated the involvement of RGS16 and RGS18 in megakaryopoiesis and/or platelet 
function (see [107] for more details). RGS18 was actually present in progenitor and 
mature myeloerythroid and lymphoid lineage blood cells [122]. 
 
GRKs in hematopoietic cells  
GRKs are critically involved in immune response through regulation of cytokine 
receptors in mature leukocytes, but their role in hematopoiesis is largely unknown. GRK2 
phosphorylates and regulates several chemokine receptors such as CCR5, CCR2b, 
CXCR4 [49, 123]. Altered GRK2 levels are observed in several cardiovascular and 
inflammatory pathologies. Interestingly, GRK2 is highly expressed in different cellular 
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types of the immune system [124]. In T cells and monocytes decreased GRK2 levels 
correlate with enhanced ERK activation and cell migration in response to chemokines 
[125-126] while in some other cellular models GRK2 down-regulation impairs migration 
[127]. Moreover, GRK6 is highly expressed in vertebrate immune organs and peripheral 
blood cells [128-129]. Interestingly, GRK6 knockout mice show increased severity of 
acute inflammatory arthritis [130] and colitis [131] because of enhanced granulocyte 
chemotaxis, and develop autoimmune diseases due to impaired macrophage engulfment 
[132]. GRK6 regulates chemotaxis through SDF/CXCLs-CXCR4 [126, 133-134] 
leukotriene B4-induced CGRP receptor [135] and BLT receptor [136] activation. Also, it 
has been reported that the expression and activity of GRK6 change during differentiation 
of the promyelocytic cell line HL-60 [137] suggesting the potential involvement of GRK6 
in earlier leukocyte development. Recently, it has been shown that GRK6 knockout mice 
exhibit lymphocytopenia, loss of the hematopoietic stem cell (HSC) and multiple 
progenitor populations, demonstrating the importance of GRK6 in regulation of 
hematopoietic stem cell self-renewal [138]. 
 
Arrestin proteins in hematopoietic cells 
In the immune system, β-arrestin scaffolds perform key roles through the negative 
regulation of G protein–mediated responses, promotion of chemotaxis, regulation of 
exocytosis and degranulation, and signal dampening through sequestration of pathway 
components [139]. β-arrestins regulate macrophage chemotaxis both by desensitizing 
chemokine CCL2-induced Ca2+ signaling and by scaffolding ERK1/2-dependent 
assembly of the actin cytoskeleton in pseudopodia [49, 140]. In polymorphonuclear 
leukocytes, β-arrestin1–bound hematopoietic cell kinase (c-Hck) and proto-oncogene c-
Fgr regulate IL-8 CXCR1 receptor–stimulated granule exocytosis [141], similar to the 
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reported role of a β-arrestin1–c-Yes complex in the control of endothelin-1–stimulated 
translocation of exocytic granules containing the glucose transporter GLUT4 [142]. 
Isolated polymorphonuclear leukocytes lacking β-arrestin2 exhibit increased basal and 
lipopolysaccharide-stimulated release of the inflammatory cytokine TNF-α and IL-6 
[143], perhaps due to the loss of tonic inhibition of NF-κB transcriptional pathways by β-
arrestin2–dependent sequestration of IκBα and IκB kinases [144]. β-Arrestin2 also 
negatively regulates the activity of natural killer cells by recruiting the protein-tyrosine 
phosphatases SHP-1 and SHP-2 to the inhibitory killer cell immunoglobulin-like receptor 
2DL1 (KIR2DL1) [145]. Zebrafish embryos lacking β-arrestin1 fail to undergo 
hematopoiesis and exhibit severe posterior defects resulting from downregulation 
of cdx4, a homeobox transcription factor that specifies the hematopoietic lineage by 
modulating hox gene expression [146]. 
 
GPCR signaling and cancer 
The balance between activation and de-activation in GPCR signaling is crucial for cell 
homeostasis and loss of it may recur in pathologies. Several studies indicate that GPCRs 
and their signaling pathways control different aspects of cancer progression. As stated 
before there are many current drugs that target GPCRs [147] but conversely there are no 
current drugs for treatment of cancer of specialized GPCRs. GPCR activity can be altered 
in cancer through changes in their expression levels or in increased production and/or 
secretion of their ligands, also through gain-of-function activating or inactivating 
mutations (estimated to be present in 20% of human cancer), by both tumor cells and 
surrounding stromal cells (see reviews [148-153]). The Catalogue of Somatic Mutations 
in Cancer [154] reveals the presence of mutations in multiple GPCRs. Among those 
GPCRs: CXCR5, GPR183, GPR153, GPM8, DRD2, LPHN3, P2RY2, P2RY8, FZD1, 
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F2RL2, NPSR1 and GPRC6A are found in hematopoietic and lymphoid tissues [153]. A 
more recent study has approached the expression of GPCR in cancer cells using TaqMan 
qPCR [155]. The analysis revealed that certain cancer cell types may possess a “GPCR 
signature” with no mutations but altered expression of several GPCRs. The authors found 
that in patients with B-cell Chronic Lymphocytic leukemia (CLL), cells express 106 
common GPCRs but some of them, e.g. GPR92, GABBR1, CNR2, CELSR1 are 
overexpressed compared to normal B cells [155]. Additionally, certain GPCRs (e.g., 
CD97 and GPR56) are found highly expressed in multiple types of cancer, including 
AML [156-157]. Moreover, high expression of CXCR4 has been associated as prognostic 
predictor associated with poorer clinical outcome [158-160].  Malignant transformation 
and oncogenesis can also be obtained by expression of G proteins in constitutively active 
state (GTP-bound) either by blocking the ability to hydrolyze GTP (i.e., GTPase-deficient 
mutants) or by reducing its sensitivity to the action of GAPs (i.e., GAP-insensitive). 
GNAS is the most frequently mutated G proteins in human cancer ([161], see references 
herein). Active mutations in GNAS have been found in pituitary tumors, thyroid 
adenomas, colon cancer, pancreatic tumors, hepatocellular carcinoma, parathyroid cancer 
and a few others. The most frequent gain of function mutation of GNAQ or GNA11 is 
found in around 60% of ocular melanomas, in meninges (59%), in most blue nevus of the 
skin (83%), and in a subset of cutaneous melanomas linked to chronic sun-induced 
damage (around 6%). GNA11 and amphiregulin (AREG) are also downregulated in B-
lineage acute lymphoblastic leukemia (B-ALL) [162] and GNA15 is significantly 
mutated in skin melanoma. Of interest, mutations in GNA13 are found in a significant 
amount of cancers derived from hematopoietic and lymphoid tissues obtained from a 
whole genome study data from COSMIC v62, in addition to GNAI1 and GNAI2 [153]. 
In fact, suppressive mutations in G13 and its downstream effector Rho were found in 
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Burkitt's lymphoma and diffuse large B- cell lymphoma (DLBCL), which led to suggest 
that in fact these proteins act as tumor suppressors. On the other hand, RGSs can function 
as both inhibitors and promoters of cancer progression in breast, ovarian, lung and 
prostate cancer as they can function as GAP or GAP-independent mechanisms for G 
proteins and GPCR signaling pathways. For example, RGS1 expression in DLBCL was 
associated with poor prognosis [163]. RGS13 is increased in adult T cell 
leukemia/lymphoma [164-165]. Adding another layer of complexity, changes in GRKs 
expression or activity will have an impact on the amplitude of GPCR signaling and in 
turn mediate tumorigenesis. Recently reviewed in Nogués et al. [166], GRKs have been 
suggested to be relevant regulators of cancer progression, in particular due to their role 
as main modulator of chemokines. Specifically, changes in GRK2 levels or functionality 
have been reported to affect mitogen-activated protein kinase (MAPK)/ERK activation 
and cell proliferation in different ways, depending on the cell type and mitogen stimuli 
involved. The mechanisms underlying such effects can be varied, including “canonical” 
desensitization of G-protein–dependent MAPK stimulation by GPCR, modulation of 
GPCR-β-arrestin-MAPK cascades or of GPCR crosstalk with epidermal growth factor 
receptor (EGFR) or other growth factor receptors or by directly interacting and/or 
phosphorylating non-GPCR cellular partners [167].  Moreover, GRKs appear to play a 
central role in tumor endothelium functionality and in the homing of immune cells to the 
tumor microenvironment. Thus, it is tempting to suggest that concurrent changes in the 
dosage of different GRKs in vascular endothelial cells and in circulating monocytes and 
other immune cell types might cooperate in fueling tumor progression [166]. 
Finally, acting as a scaffold protein, β-arrestin1 and β-arrestin2 are also important for 
both initiation and progression of tumors. In particular, β-arrestin2 is influential in 
chronic myeloid leukemia (CML) by inhibiting the Wnt/β catenin pathway [168-169]. On 
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the other hand, β-arrestin1 has been shown to mediate nicotine-induced metastasis 
through e2f1 [170], ovarian cancer cell invasion though β-catenin [171] and breast cancer 
through hypoxia-inducible factor 1 (HIF-1)-dependent vascular endothelial growth factor 
(VEGF) expression [172]. 
Besides the presence of different mutations in GPCRs and their signaling proteins, 
changes in expression levels or activity of these proteins can also regulate important 
cellular functions necessary for cancer, such as proliferation, apoptosis and migration. Of 
particular interest is the fact that many different types of cancer that involves 
inappropriate GPCR signaling pathways described before have an altered Wnt/β-catenin 
pathway in common [173]. Wnt signaling plays critical roles in development and 
diseases. In fact, Wnt/β-catenin signaling contributes to the transformation of 
hematopoietic stem cells (HSC) into LSCs [174]. It is clear that a comprehensive picture 
of the complex of signaling pathways by GPCR is needed to design signaling-biased 
proteins with scientific and therapeutic potential. 
GPCR signaling in AML 
As mentioned before, AML is a heterogeneous disease with multiple molecular pathways 
driving its progression and the impact of GPCR signaling proteins is just starting to be 
investigated (Table 1).  
 
GPCRs in AML 
A recent analysis using next-generation sequencing (RNA-seq) has addressed the analysis 
of GPCRs in AML [157]. In a significate cohort of AML patients (n=772), Maiga et al. 
investigated the expression of GPCRs (transcriptome) in samples from bone marrow and 
peripheral blood and compared it with normal CD34-positive cells. They found as much 
as 30 different GPCRs upregulated and 19 GPCRs downregulated in the primary AML 
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cells. The upregulated GPCRs included the adhesion family (EMR1, EMR2, CD97 and 
GPR114), as well as members of the chemokine receptor family (CCR1, CCR2, CCR7, 
CCRL2, CXCR1 and CXCR4) and some members of the purinergic receptor family like 
P2RY2 and P2RY13. Among those, a key GPCR in AML seems to be CXCR4. In an 
independent work, Spoo et al. found that AML patients with low CXCR4 expression, as 
assessed by flowcytometry, had a significantly longer relapse-free survival and overall 
survival than patients with intermediate or high CXCR4 expression [159]. Moreover, 
receptor blocking with CXCR4 antagonists such as plerixafor increase remission rate for 
patients undergoing chemotherapy and have a positive effect on stem cell mobilization 
with G-CSF in transplanted patients [175-176]. As for the purinergic receptors, it was 
shown that higher expression of the purinergic receptor  P2RY14 is linked to relatively 
poor survival compared to AML patients having lower expression [177]. Although this 
receptor has not been studied much in hematopoietic malignancies, it seems to have a role 
in the localization of hematopoietic stem cells (HSCs) and in promoting regenerative 
capabilities following injury. The authors’ show that cells that displayed increased levels 
of expression of P2RY14 show resistance to PI3K/mTOR inhibition. The PI3K/mTOR 
pathway is the second most frequently deregulated pathway in a majority of cancers and 
it is one of the characteristics of the AML cells. They also show that the inhibitory effect 
of P2RY14 involved the activation of ERK pathway.  On the other hand, the adhesion 
GPCR family member CD97 is a well-known LSC specific marker in AML [178]. It is 
frequently expressed in CD34+CD38- LSC and its expression correlates with poor 
chemotherapy effect and prognosis, and higher recurrence rate [156, 178].  Mutations in 
the FLT3 gene, which is a land-mark of AML, is associated with AML samples with high 
levels of CD97 expression [156]. Moreover, CD97 was recently reported to be a critical 
regulator of AML stem cells [179], [178]. Martin et al. [179] verified that CD97 had 10-
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fold higher expression on LSC-enriched (CD34+CD38-) blasts, as assessed by 
flowcytometry, compared to HSCs in all AML patients (n = 30) inspected. Another recent 
study to monitor minimal residual disease after AML treatment, also found increased 
gene expression levels of CD97 (and also CX3CR1/GPR13) among 22 markers 
aberrantly expressed in leukemic cells from 157 AML patients [180]. The authors suggest 
that these markers can help to discriminate between residual cells and normal cells.  
Another adhesion receptor found [157] to be correlated to AML is GPR56. GPR56 is 
under-expressed in AML patients’ cells compared to normal CD34-positive cells, 
however high expression of GPR56 has previously been reported as an LSC-specific 
signature, as assessed by xenografting primary human AML cells into immunodeficient 
mice, for AML patient samples (n = 16) [7]. Moreover, high GPR56 expression level on 
AML LSC was recently reported to have high repopulating capacity and thus contributes 
to the development of AML in xenograft studies in mice [181-182]. The highly expressed 
GPR56 LSC signature was associated with various high-risk genetic lesions and poor 
outcome [182]. GPR56 has also been associated to the maintenance of HSCs [183]. In 
the case of the GPR84, increased levels of the receptor were found in AML LSCs 
compared to normal cells [178, 184]. The same study showed that GPR84 sustained 
aberrant β-catenin signaling and that GPR84 impaired stem cell leukocyte function and 
inhibited the development to an aggressive and drug resistant subtype of AML. Another 
upregulated receptor in AML is the proton sensing G protein coupled receptor 132 
(GPR132), also termed G2A [157]. Interestingly, the GPR132 agonist ONC212 reduced 
cell viability in AML cells, thus GPR132 is a potential therapeutic GPCR target in 
leukemia [185-186]. The involvement of GPR132 in AML have in fact prompted M.D. 
Anderson and Oncoceutics [187] to  declare their intention to bring to Phase I and Phase 
II clinical trials ONC212 for patients with refractory acute myeloid leukemia (AML).  
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Several downregulated GPCRs that were found in the study of Maiga et al., also belonged 
to the adhesion GPCR family (including GPR125, GPR126, LPHN1 and CELSR3). In 
addition, protease-activated and Frizzled family receptors were found lower expressed in 
AML patient cells compared to normal CD34-positive cells [157]. 
As mentioned before, it has been long assumed that relapse of AML arises from a 
population of leukemia stem cells (LSC) that were dormant and therefore likely protected 
from chemotherapy. But this concept has been challenged by a recent study [188] that 
provides evidence that, in fact, LSCs are not present after chemotherapy. On the contrary, 
they found a small population of cells that they named “leukemic regenerating cells” 
(LRCs) that were only present after chemotherapy and not in healthy regenerating cells 
in the bone marrow (HSC). These cells had a gene expression profile distinctly different 
from that of LSCs. One feature of these cells was the functional association and the 
production of several G-protein-coupled receptors (GPCRs), among them elevated levels 
of GPR1, GPR139, DRD2, GRM5 and GPR148. The authors found that antagonist 
treatment of one of these receptors, DRD2, had profound effects on regenerating LRCs 
in chemotherapy-treated mice. The possibility to use markers of LRC will discriminate 
between relapsing versus disease-free survival in human AML patients. It also highlights 
the importance of identifying specific markers to monitor resistance after chemotherapy. 
Opening also the chances for specific therapy directed towards the small population of 
regenerating cells, as stated by the editor [189].  
G proteins in AML 
As described above, CCR1, CCR2 and CXCR1 may interact with G15/16, which 
subsequently bring about phosphorylation and transcriptional activation of NF-κB [38, 
102-103]. NF-κB is often found constitutively activated in AML patients’ cells and is 
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associated with resistance to apoptosis and increased proliferative signaling (reviewed 
in[190]). Thus, receptor blocking of one or several of these chemokine receptors and/or 
selective inhibitor drug against the G15 protein may be a therapeutic option, which 
dampen downstream signaling and NF-κB activation. Interestingly, by performing gene 
expression profiling of the LSC-enriched CD34+ fraction from AML patients (n=46), de 
Jonge et al. found high transcription level of G15 (GNA15), as well as ankyrin repeat 
domain 28 (ANKRD28) and UDP-glucose pyrophosphorylase (UGP2), which was 
significantly linked to poorer overall survival in two other independent larger cohorts 
(n=163 and n=218) of AML patients with normal karyotype [191]. Approximately 40-50 
% of all AML patients show no aberrant karyotype [191]. Thus, G15 transcription 
expression analysis may be useful for risk-benefit evaluation of potential allotransplanted 
patients with normal karyotype AML.  
 
Wang et al. previously demonstrated that the Wnt/β-catenin signaling pathway is required 
for mixed-lineage leukemia (MLL)-AF9-induced AML in mice [192]. MLL- 
translocations and fusion genes are found in approximately 10 % of AML cases and are 
generally associated with poor prognosis (reviewed in [193]). Interestingly, a crucial role 
for Gαq and downstream β-catenin signaling in maintenance of AML-LSC were recently 
reported [174]. By using selective inhibition of Gαq, as assessed with the GP-antagonist 
2A inhibitor peptide of Gαq or shRNA silencing, in pre-LSC and leukemic cells it was 
demonstrated that Gαq promotes proliferation and extends survival of leukemic cells both 
in vitro and in vivo [174]. Interestingly, Gαq-inhibition was linked to reduced expression 
of mitochondrial complex 1 subunits and impairment of the oxidative phosphorylation in 
the myeloid leukemic cells. The results agree with previous data that show regulation of 
mitochondria respiration capacity by Gq proteins [33]. Thus, leukeomogenesis of AML-
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LSC may be associated to dysfunctional mitochondrial function via Gαq- and subsequent 
β-catenin- signaling. In another study, G11 (GNA11) [162] was found downregulated in 
AML patients together with amphireguling (AREG), albeit the results were found in only 
two patients.  On the other hand, functional platelet-activating factor (PAF) receptor and 
Gq protein were detected in AML and ALL patient cells [194]. In a recent study, utilizing 
parallel targeted next generation sequencing, changes in GNAQ expression were found 
in childhood AML (n=20) compared to adult AML [195]. In another study searching for 
GNAQ-Q209 mutation in different tumors including AML, breast, colorectal, lung, 
glioma, ovary, pancreas, thyroid and melanomas, the mutation was only found in blue 
nevus samples (n=13) [196]. Hence, it seems that the GNAQ activated mutation can only 
be found in specialized cells. Thus, the potential of GNAQ and GNA11 as a marker for 
AML is promising, but it will need further investigation.  
 
RGSs in AML 
Given the important role that RGSs have in controlling chemokine signaling and their 
pattern of expression it is plausible that they play an important role in tumor induction or 
proliferation of hematopoietic cells.  In fact, it was detected decreased expression of 
RGS2 in AML patients that also presented fetal liver tyrosine kinase 3 internal tandem 
duplications in the juxtamembrane domain (Flt3-ITD) [197]. The authors demonstrated 
that forced expression of Flt3-ITD in myeloid cell lines downregulated RGS2, whereas 
overexpression of RGS2 inhibited Flt3-ITD-induced phosphorylation of Akt and clonal 
growth of myeloid cells. RGS2 mRNA expression in primary AML bone marrow samples 
was repressed in the majority of cases compared with controls from healthy donors, also 
in the absence of activating Flt3 mutations. They also presented a strong correlation of 
RGS2 expression and myeloid differentiation in several leukemia cell line models. On 
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the other hand, the authors demonstrated that the cytoplasmic RGS2 levels could regulate 
Gαq activity and thus serve as a modulator of GPCR signaling and receptor tyrosine 
kinase crosstalk in AML. Thus, RGS2 and other RGSs can emerge as new targets for 
AML therapies. Interestingly, Mosakhani and collaborators identified miR-363 as a 
miRNA in samples from patients that respond poorly to chemotherapy in AML [198]. 
The levels of miR-363 are known to increase in CD4+ cells from peripheral blood 
mononuclear cells [199], and one of the targets of miR-363 is RGS17. RGS17 is 
associated with chemoresistance, and its high expression leads to a reduced susceptibility 
to chemotherapeutic cytotoxicity [200]. As stated before, other RGSs are expressed 
specifically in hematopoiesis, for instance RGS18, thus it may be reasonable to think that 
future studies may uncover other RGS targets for AML.  
 
GRKs in AML 
Although there is not a clear link between the GRKs and AML, multiple small molecule 
kinase inhibitors are currently being developed for this disease [201]. It has been 
described that Akt, a critical substrate of PI3 kinase, is activated in AML blasts [202]. 
Moreover, aberrant PI3K/Akt/mTOR signaling has been implicated in many human 
cancers, including AML [203]. Efforts to exploit pharmacological inhibitors of the 
PI3K/Akt/mTOR cascade are currently under investigation. Interestingly, GRKs has been 
described to interact and modulate PI3K function [54, 204]. 
 
Wnt signaling in AML 
As we have mentioned before, growing evidences from both preclinical and clinical 
investigations reveal the critical role of Wnt signaling for the development of many 
cancers and their response to chemotherapy [173]. Specifically, Wnt inhibitors reduce 
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proliferation and chemoresistance of AML cells in culture or co-culture with bone 
marrow stroma cells. Thus, active Wnt signaling appears to play an important role in the 
propagation/acceleration of AML and has been shown to be an important secondary 
oncogenic event to transform pre-LSCs into LSCs in mouse models of AML [205]. 
Interestingly, it has been described that Wnt-pathway inhibitors, which inhibit the 
interaction between β-catenin and LEF1, selectively induce cell death in AML cell lines 
and primary AML blasts [206]. 
 
Protein biomarkers for AML 
The perturbed expression of GPCRs and signaling proteins described previously are 
examples of potential biomarkers that can be used in diagnostics or prognostic evaluation 
of individual cancer patients. In AML, new biomarkers are needed for better classification 
and hence further personalized treatment of AML patients. A biomarker or a biomarker 
panel that can predict the therapy response would help the hematological clinicians to 
better identify patients that will benefit from allo-HSCT early during the first remission 
after standard chemotherapy.  
A biomarker can take many forms (e.g. gene mutations or altered abundances or presence 
of cells, transcripts, proteins or metabolites). Protein biomarkers for prognostication, 
disease monitoring and therapeutic guidance have great potential to improve clinical 
assessment of cancer, also in AML [207-208]. Over the past years, the major focus in 
biomarker studies have been genetic approaches. Likewise, most of the current potential 
biomarkers for aberrant GPCR and downstream signaling molecules in AML, as given in 
Table1, were found by genomic- and transcriptomic-based approaches. Hitherto, protein 
biomarkers in the clinical practice are often assessed with non-MS techniques (mainly 
immunoassay and immunohistochemistry) [209] [210]. An example is flowcytometric 
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drug monitoring of therapeutic surface levels of the GPCR-linked protein biomarker 
CXCR4 after plerixafor administration to AML patients [175-176]. However, the poor 
prognostic CD97 biomarker on LSC-enriched (CD34+CD38-) AML blasts was detected 
by LC-MS and validated by flow cytometry [179], [178]. Many biomarkers candidates 
from proteomic studies have been suggested but very few have been implemented into 
the clinic [211]. While technical limitation previously could be used as explanation to 
why proteomics has not resulted in many new clinical biomarkers, it may currently rather 
be a result of poor study design. This can include the use of underpowered studies, 
insufficient understanding of the analytical evaluation criteria required to pass through 
the approval pipeline by the U.S. Food and Drug Administration (FDA), unreproducible 
pre-analytical sample processing and/or inappropriate statistical and experimental design 
[211-212]. Moreover, earlier AML discovery-based biomarker studies have to a large 
extent been performed with low performance 2D-PAGE based approaches combined with 
MALDI-TOF or LC-MS, which results in a low number of quantifiable proteins and 
potential biomarkers compared to what is achievable with liquid chromatography on 
modern mass spectrometers like Q Exactive HF Orbitrap LC-MS/MS system [213]. 
Interestingly, by using the state-of-the-art Q HF-X mass spectrometer it is possible to 
identify 5000 phosphopeptides and 55000 peptides (5900 proteins) with only short 15 
min and 30 min LC-MS/MS run, respectively [213]. Mass spectrometry-based protein 
quantification may thus be applied as an efficient tool for improved clinical assessment 
of cancer, and step by step protocols for handling primary AML samples have recently 
been published [214-215]. The global phosphoproteome study by Schaab et al. 
demonstrated how a phosphosignature can predict the response to the tyrosine kinase 
inhibitor Quizartinib, as currently assessed in clinical trials [216]. For patients with non-
small-cell lung cancer a proteomic signature was also found to have predictive and 
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therapeutic value in a phase-III trial [217]. Thus, this might be the era afore a big break-
through in clinical application of proteomics-based biomarkers.  
We have previously reviewed the proteomics-based scientific contributions to 
AML research with main focus on AML patient material and biomarkers [218], but 
perhaps due to reasons mentioned above, only one protein (CLCX4) related to the GPCR 
signaling pathway was proposed as a potential biomarker.   However, we envision that 
e.g. stimulation of different GPCR pathways in different AML subgroups, and subsequent 
targeted analysis of several downstream GPCR mediators will unveil how GPCRs and 
the mediators are differently activated or altered in AML subsets of this heterogeneous 
disease. Here, the sensitive and high throughput quantification technology named Parallel 
Reaction Monitoring (PRM) can be used to measure the abundance of tens to hundreds 
of targeted peptides from each AML patient in a short time. In brief, PRM involves 
isolation of the target precursor ion in the quadrupole (Q1), fragmentation of the selected 
ion in the collision cell (Q2) and detection of the generated product ions in the orbitrap 
[219]. The targeted PRM method can be used for quantification of aberrant GPCR-
mediated protein and phosphorylation dynamics in signalling pathways in a sensitive and 
specific manner without the need of antibodies.  
 
Conclusion 
As described elsewhere herein, there is compelling evidence for involvement of aberrant 
GPCR expression and perturbed GPCR-mediated signaling in the development of cancer. 
Many of these measurable indicators of abnormal expression have large potential as 
predictive markers of therapy response, and thus can be used for therapeutic guidance of 
cancer patients. To our knowledge, no large proteome AML patient cohorts with focus 
on GPCR-signaling have been published. Regarding AML, testing of available approved 
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drugs as well as synthesis of new small molecule therapeutics against AML enriched 
GPCRs or GPCR signaling proteins are warranted [147]. We postulate that mass 
spectrometry-based protein profiling of primary AML cells will accelerate the discovery 
of potential GPCR related biomarkers for AML. Targeted quantitative proteomics 
approaches (e.g. PRM) can then be used to accurately and simultaneously measure the 
abundance of 10s of AML-disease related proteins (including phosphorylation status and 
other PTMs) in large patient cohorts. This will lead to new information regarding the 
significance and clinical potential of these AML-disease related proteins as markers for 
prognostication, disease monitoring and therapeutic guidance. 
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Figure. 1. GPCRs are expressed in hematopoietic cells. Receptors stimulate 
heterotrimeric G proteins by promoting GDP to GTP exchange in the Gα subunit and 
dissociation from the βγ dimer. Both Gα and βγ initiate signaling through different 
effector proteins. Activated GPCRs are phosphorylated by GRKs on the internal loops 
creating recognition sites for β-arrestins that can in turn act as adaptor proteins initiating 
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alternative signaling cascades. Interestingly, a crosstalk between GPCRs and Wnt/β-








 Experimental effect in AML Reference 
CXCR4  Low expression correlated with longer relapse-free survival. 
Upregulation in AML. 
High CXCR4 expression is associated with poorer clinical outcome. 
Pharmacological target for HSC mobilization from bone marrow. 









   High expression on primary AML cells. [157] 
GPR84   High expression is linked to poor prognosis. Stimulates aberrant -catenin 
signaling for maintenance of AML-LSC leukemogenesis. 
[184],[178]  
CD97  Critical regulator of AML stem cell. High expression on LSC-enriched 




GPR56  LSC-specific signature. 
High repopulating capacity in xenograft studies in mice. 
Under-expression in AML patients. 







 Purine receptor family. Upregulated in AML.    [157]  
P2RYY14  High expression correlates with poor survival AML. 















 Adhesion family receptors. Upregulated in AML. 
 
Upregulated receptor in AML. 





GNA15  High transcription level with ANKRD28 and UGP2, linked to poorer 
overall survival. 
[191] 
GNAQ   Stimulates proliferation and survival of AML-LSC. 
Activate -catenin signaling and increases expression of mitochondrial 
complex 1 subunits in AML-LSC. 
Mitochondrial disfunction. 
Changes in GNAQ expression were found in childhood AML compared to 
adult AML. 
Gq protein and Platelet-activating factor (PAF) receptor proteins were 








GNA11  Downregulated in AML patients together with AREG. [162] 
RGS2  Decreased expression in AML patients with Flt3-ITD. [197] 
RGS17  Putative inhibition by miR-363 in patients that respond poorly to 
chemotherapy in AML. 
[199] 
Wnt signaling  Wnt inhibitors reduce proliferation and chemoresistance of AML cells. 
Needed for MLL-AF9 induced AML in mice. 
Wnt-pathway inhibitors induce cell death in AML cell lines and primary 
AML blasts. 
[173], [205] 
[192]  
[206] 
